Letermovir exposure in transplant patients with end-stage renal disease on renal replacement therapy,Journal of Antimicrobial Chemotherapy

当前位置： X-MOL 学术 › J. Antimicrob. Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Letermovir exposure in transplant patients with end-stage renal disease on renal replacement therapy
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2021-09-02 , DOI: 10.1093/jac/dkab316
Nora Isberner ₁ , Ruth Van Daele _{2,

3} , Hartwig Klinker ₁ , Sabrina Kraus ₄ , Fatemeh Aghai ₁ , Greet De Vlieger ₅ , Dirk Kuypers ₆ , Yves Debaveye ₅ , Isabel Spriet _{2,

3}

Affiliation

Letermovir is an antiviral drug approved for the prevention of cytomegalovirus (CMV) infection and disease in adult seropositive patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT).¹^,² Additionally, off-label use of letermovir for treatment of CMV disease or DNAaemia after allo-HSCT and solid organ transplantation (SOT) has been reported.³

中文翻译：

接受肾脏替代治疗的终末期肾病移植患者的莱特莫韦暴露

莱特莫韦是一种抗病毒药物，被批准用于在接受异基因造血干细胞移植 (allo-HSCT) 的成人血清阳性患者中预防巨细胞病毒 (CMV) 感染和疾病。¹^,²此外，已经报道了在allo-HSCT 和实体器官移植（SOT）后使用莱特莫韦治疗CMV 疾病或DNA 血症的标签外使用。³

更新日期：2021-09-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11